HYULIM A-TECH Co., Ltd.

EDMONTON, Alberta, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Quest PharmaTech Inc. (TSX-V:QPT) (“Quest” or the “Company”) today announced the results of its October 8, 2024 annual general meeting of shareholders. The Company announces the following four directors have been elected to the Company’s Board of Directors: J. Mark Lievonen, C.M., FCPA, FCA, LLD Jeffrey Shon, J. DBradley J. Glass J.DMadi R. Madiyalakan, Ph.D. At the meeting, shareholders reappointed the Company’s auditors, Kingston Ross Pasnak, LLP. “I would like to thank all of our Board members for their service to the Company,” said Dr. Madi R. Madiyalakan, Chief Executive Officer of Quest. “I am confident that Quest’s Board of Directors will be able to help the Company execute its business strategy to add value to our shareholders.” Approximately 75,392,253 shares were voted for the Company’s shareholder meeting representing approximately 44.58% of the Company’s shares eligible to vote. On a corporate matter, Quest announces the granting of 1,800,000 stock options to Directors and Officers, all at a volume weighted average exercise price of $0.05 per common share, expiring 10 years from the date of grant, subject to TSX Venture Exchange approval. About Quest PharmaTech Inc. Quest PharmaTech Inc is a publicly traded, Canadian based biopharmaceutical company (QPT: TSX-V) developing products to improve the quality of life through investee companies and proprietary technologies. Quest is developing the proprietary MAb-AR9.6 targeting MUC16 as theranostic agents for cancer. MAb-AR9.6 was licensed from the University of Nebraska Medical Centre and currently is in late preclinical stage development. The Company also has a 42.5% ownership interest in OncoQuest Inc. which sold its immunotherapy technology assets to Korea-based Dual Industrial Co, Ltd. in April 2020. Quest also has a 23% ownership interest in OncoVent, a Chinese joint venture developing antibody-based immunotherapeutic products for cancer for the Greater China territory. To learn more, visit www.questpharmatech.com. Forward Looking Statements Statements on the development and potential of the Company’s MAb AR9.6 product candidate constitute forward-looking statements. Such statements are based on the current expectations of management and inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond Quest’s control. These risks include the achievement of forecasted development milestones, that actual results may vary once the final and quality-controlled verification of data and analyses has been completed and other risks disclosed in the Company’s Management’s Discussion & Analysis and other public fillings at www.sedarplus.ca. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. The reader should not place undue reliance, if any, on any forward-looking statements included in this news release. These statements speak only as of the date made and Quest is under no obligation and has no intention to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable law. For further information: Dr. Madi R. Madiyalakan, CEO, Quest PharmaTech Inc.Tel: (780) 448-1400, Email: madi@questpharmatech.com Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

EDMONTON, Canada I January 23, 2024 I Quest PharmaTech Inc. (TSXV: QPT ) ("Quest" or the "Company") a Canadian based pharmaceutical company developing products to improve the quality of life through investee companies and proprietary technologies, announced that it has received information that the Phase III clinical trial of oregovomab for the treatment of Ovarian Cancer, sponsored by CanariaBio Inc ("CAB"), has received recommendations from the Data Safety Monitoring Board (DSMB), an independent committee appointed by CAB to advise on the trials, to discontinue the clinical trial after conducting a futility evaluation for interim progression free survival in study subjects. The DSMB also expressed the opinion that due to the characteristics of immunotherapy drugs, there is a possibility of significant efficacy in overall survival and recommended that follow up observations be continued in study subjects. Quest holds bonds of Korea-based OQP Bio Inc. (the "OQP Bonds") received in connection with the sale of the immunotherapy technology assets, including oregovomab, of investee company OncoQuest Inc. in April 2020. Quest continues to pursue the monetization of the OQP Bonds and is currently engaged in discussions with CanariaBio M Co. Ltd. ("CABM"), the parent company of OQP Bio as well as KOSDAQ listed CAB. The OQP Bonds are currently illiquid and there can be no assurance that the Company will be successful in negotiating monetization terms with CABM for its OQP Bio bonds, that any definitive agreement will be entered into for such monetization, or that the Company will ultimately be able to monetize all or any part of its bonds . Quest is also in discussions with CABM on options available for Quest to continue to support the oregovomab clinical program. About Quest PharmaTech Inc. Quest PharmaTech Inc is a publicly traded, Canadian based biopharmaceutical company (QPT: TSX-V) developing products to improve the quality of life. The Company has a 42.5% ownership interest in OncoQuest Inc. which sold its immunotherapy technology assets to Korea-based Dual Industrial Co, Ltd. in April 2020. Quest also has a 23% ownership interest in OncoVent, a Chinese joint venture developing antibody-based immunotherapeutic products for cancer for the Greater China territory. Quest is also developing proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. AR 9.6 was licensed from University of Nebraska and currently is in late preclinical stage. To learn more, visit www.questpharmatech.com SOURCE: Quest PharmaTech

DUBLIN, Oct. 21, 2022 /PRNewswire/ -- The "Drug Injection Devices to 2028" report has been added to ResearchAndMarkets.com's offering. Drug Injection Devices to 2028 - What You Will Learn What are the dynamics of the shifting landscape for injectable drug delivery and the market impact of new and evolving syringes and injectors by therapeutic indication? What are the market drivers influencing syringe and injector device designs, feature/functionality, product branding, competing technologies and commercial development? What are the key characteristics of the major injection device market segments and what is the impact of market demographics, and competing business strategies? What is the current market for syringe and injector demand by indication and therapy and what will it be in 2028? Who are the leading injection device companies, and what are their product development activities, business strategies, and corporate alliances and affiliations? What is the impact of economic, technology, and regulatory factors on injectable drug delivery demand? The correlation between chronic conditions and the benefits of patient self-administration continues to influence therapeutic product decisions, managed care initiatives and regulatory actions. Drug injection device designs are increasingly being based on the results of human engineering inputs and patient preference research. Branding and packaging choices are more frequently being driven by data sources historically employed by consumer product marketers. For drug developers and device suppliers, the implications of these trends are influencing product development methodology and changing supply chain relationships. Decisions regarding as-supplied packaging that were once considered boilerplate have moved to the early stages of the development process. Key Topics Covered: Executive Summary The Market Opportunity Injectable Drug Demand Drivers Syringe Economics Drug Self-injection - Device Technology Factors Device Selection - Stability and Material Issues Competitive Landscape Injection Device Suppliers Capabilities and Market Presence North America Europe Asia Commercial Injection Device Classes - Strategic Analysis Autoinjectors Manual Injection Autoinjectors Disposable Autoinjectors Reusable Autoinjectors Fixed Dose Autoinjectors Fixed Dose/Reusable Injectors Variable Dose Autoinjectors Syringe-based Autoinjectors Cartridge Base Autoinjectors Automated Injection Autoinjectors Product Specific Autoinjectors Dual Chamber Devices Dual Chamber Syringes Dual Chamber Pen Injectors Needle-free Injectors Pen Injectors Standardized Pen Platforms Pen Classes Reusable Pens Disposable Pens Drug/Device Combination Products Prefilled Syringes Glass Prefilled Syringes COC Prefilled Syringes Subcutaneous Infusion Devices Injection Device Selection Criteria Fixed vs Variable Dose Devices Lyophilized Drugs/Reconstitution Needle Configuration Strategies Disposable Drug Cartridges Human Engineering/Ergonomics Branding/Private Labeling Drug Injection Device Market Segment Analysis & Forecasts Anticoagulants Antivirals Autoimmune Diseases Rheumatoid Arthritis Psoriasis Stelara (Ustekinumab) Multiple Sclerosis Emergency Medicine Hematopoietics Hormone Replacement Osteoporosis Reproductive Health Vaccines Injectable Drug Therapeutics - Market Factors Regulatory Issues Device Branding Patient Compliance and Ease of Use Healthcare Economics Company Profiles For more information about this report visit Media Contact: Research and Markets Laura Wood, Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1904 Fax (outside U.S.): +353-1-481-1716 Logo: SOURCE Research and Markets